Pharma Mergers Will Be More Defensive Going Forward, Abbott CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor wariness on the economic benefit of acquisitions will slow consolidation in the industry, White tells The Economist Pharmaceutical Roundtable. Sanofi-Aventis expects that any further consolidation will result from weakness.